Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion type Assertion NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_head.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion description "[In comparison with genetically undefined patients, LRRK2 mutation carriers had more severe motor symptoms (median Unified Parkinson's Disease Rating Scale scores approximately 1.6 times higher, p<0.001), a higher rate of dyskinesia (OR 4.21, p=0.002) and use of dopamine agonists (OR 3.64, p<0.001), and less postural tremor (OR 0.21, p<0.001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_provenance.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion evidence source_evidence_literature NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_provenance.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion SIO_000772 19726410 NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_provenance.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion wasDerivedFrom befree-2016 NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_provenance.
- NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_assertion wasGeneratedBy ECO_0000203 NP760894.RAU6V7Gg_1cxuWXJX0f7fmO71UHxVvEz6Dvc2A3ePRIq4130_provenance.